Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics
Vancouver, British Columbia – (December 11th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to […]
BIOMARK ANNOUNCES PRIVATE PLACEMENT
Vancouver, British Columbia – (November 21st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000. Each Unit is composed […]
BIOMARK Announces Private Placement
Press_Release_BIOMARK_ANNOUNCES_PRIVATE_PLACMENT_May_9th_2017 (PDF)
BioMark Signs Letter of Intent for Licensing Relationship for Clinical Validation and Development
Vancouver, British Columbia – (November 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has signed a Letter of Intent (LOI) with a Chinese company named GuangDong Longhu (Longhu) related to an anticipated licensing relationship. BioMark has been in discussions with Longhu and its management […]
NEW SCIENTIFIC PUBLICATION FURTHER SUPPORTS BIOMARK’S ASSAY
Vancouver, British Columbia – (August 27th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults” has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “This […]
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest […]
NEW ADVANCES IN LIQUID BIOPSY TO INCREASE BIOMARK’S ASSAY PERFORMANCE
Vancouver, British Columbia – (August 13th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” has been published in the peer-reviewed journal Cancers. Rashid Ahmed, President and CEO, says, […]
The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics
Vancouver, British Columbia – (June 26, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that BioMark and the University of Maryland School of Medicine (UMSOM) have entered into a collaboration related to the discovery and validation of biomarkers using a combinatorial technology approach. This collaboration follows several […]
BioMark Announces Debt Settlement
Vancouver, British Columbia – (June 18th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that it has arranged a voluntary debt to share settlement (the “Debt Settlement”) with certain directors and officers of the Company in connection with existing indebtedness related to services provided to the Company […]
BIOMARK ANNOUNCES NEW PATENT GRANTED IN UNITED STATES
Vancouver, British Columbia – (May 30th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States. Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens […]